한글목차

코센틱스(일반명: 세쿠키누맙)는 면역억제제입니다. 이 약은 동결건조된 제제로, 미리 채워진 주사기 또는 펜에 채워져 있습니다. 현재 중등도에서 중증의 판상 건선(PsO), 건선성 관절염(PsA), 액와 척추 관절염(axSpA) 등 3가지 염증성/자가면역성 질환의 치료제로 승인됐습니다.

앞으로 몇 년동안 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 그레이브스병 안과 질환 시장 시나리오가 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 코센틱스의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 신생 베체트병 안질환 치료제는 코센틱스 시장 경쟁자가 될 것으로 예상되며, 가까운 시일 내에 후발 주자들이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 그레이브스 안병증 치료제 코센틱스(Cosentics) 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 그레이브스 안병증에서의 코센틱스 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 코센틱스 시장 평가

• 그레이브스 안병증 치료제 코센틱스 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 그레이브스 안병증 치료제 코센틱스 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"COSENTYX Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about COSENTYX for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the COSENTYX for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the COSENTYX for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the COSENTYX market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.

Drug Summary:

COSENTYX (secukinumab) is an immunosuppressive agent. It is formulated as freeze-dried preparation of powder solution and solution in a prefilled syringe or pen for the SC route of administration. It is a recombinant high-affinity fully human monoclonal anti-IL-17A antibody currently approved for the treatment of three inflammatory/autoimmune diseases: Moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the COSENTYX description, mechanism of action, dosage and administration, research and development activities in Graves' Ophthalmopathy.
• Elaborated details on COSENTYX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the COSENTYX research and development activities in Graves' Ophthalmopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around COSENTYX.
• The report contains forecasted sales of COSENTYX for Graves' Ophthalmopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Graves' Ophthalmopathy.
• The report also features the SWOT analysis with analyst views for COSENTYX in Graves' Ophthalmopathy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

COSENTYX Analytical Perspective by DelveInsight

• In-depth COSENTYX Market Assessment

This report provides a detailed market assessment of COSENTYX for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• COSENTYX Clinical Assessment

The report provides the clinical trials information of COSENTYX for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Graves' Ophthalmopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence COSENTYX dominance.
• Other emerging products for Graves' Ophthalmopathy are expected to give tough market competition to COSENTYX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of COSENTYX in Graves' Ophthalmopathy.
• Our in-depth analysis of the forecasted sales data of COSENTYX from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the COSENTYX in Graves' Ophthalmopathy.

Key Questions:

• What is the product type, route of administration and mechanism of action of COSENTYX?
• What is the clinical trial status of the study related to COSENTYX in Graves' Ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the COSENTYX development?
• What are the key designations that have been granted to COSENTYX for Graves' Ophthalmopathy?
• What is the forecasted market scenario of COSENTYX for Graves' Ophthalmopathy?
• What are the forecasted sales of COSENTYX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to COSENTYX for Graves' Ophthalmopathy?
• Which are the late-stage emerging therapies under development for the treatment of Graves' Ophthalmopathy?

Table of Contents

1. Report Introduction

2. COSENTYX Overview in Graves' Ophthalmopathy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. COSENTYX Market Assessment

• 5.1. Market Outlook of COSENTYX in Graves' Ophthalmopathy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of COSENTYX in the 7MM for Graves' Ophthalmopathy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of COSENTYX in the United States for Graves' Ophthalmopathy
  • 5.3.2. Market Size of COSENTYX in Germany for Graves' Ophthalmopathy
  • 5.3.3. Market Size of COSENTYX in France for Graves' Ophthalmopathy
  • 5.3.4. Market Size of COSENTYX in Italy for Graves' Ophthalmopathy
  • 5.3.5. Market Size of COSENTYX in Spain for Graves' Ophthalmopathy
  • 5.3.6. Market Size of COSENTYX in the United Kingdom for Graves' Ophthalmopathy
  • 5.3.7. Market Size of COSENTYX in Japan for Graves' Ophthalmopathy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options